Your browser doesn't support javascript.
loading
High-affinity cyclic peptide matriptase inhibitors.
Quimbar, Pedro; Malik, Uru; Sommerhoff, Christian P; Kaas, Quentin; Chan, Lai Y; Huang, Yen-Hua; Grundhuber, Maresa; Dunse, Kerry; Craik, David J; Anderson, Marilyn A; Daly, Norelle L.
Afiliação
  • Quimbar P; La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.
J Biol Chem ; 288(19): 13885-96, 2013 May 10.
Article em En | MEDLINE | ID: mdl-23548907
ABSTRACT

BACKGROUND:

Sunflower trypsin inhibitor-1 (SFTI-1) and Momordica cochinchinensis trypsin inhibitor-II (MCoTI-II) are potent protease inhibitors comprising a cyclic backbone.

RESULTS:

Elucidation of structure-activity relationships for SFTI-1 and MCoTI-II was used to design inhibitors with enhanced inhibitory activity.

CONCLUSION:

An analog of MCoTI-II is one of the most potent inhibitors of matriptase.

SIGNIFICANCE:

These results provide a solid basis for the design of selective peptide inhibitors of matriptase with therapeutic potential. The type II transmembrane serine protease matriptase is a key activator of multiple signaling pathways associated with cell proliferation and modification of the extracellular matrix. Deregulated matriptase activity correlates with a number of diseases, including cancer and hence highly selective matriptase inhibitors may have therapeutic potential. The plant-derived cyclic peptide, sunflower trypsin inhibitor-1 (SFTI-1), is a promising drug scaffold with potent matriptase inhibitory activity. In the current study we have analyzed the structure-activity relationships of SFTI-1 and Momordica cochinchinensis trypsin inhibitor-II (MCoTI-II), a structurally divergent trypsin inhibitor from Momordica cochinchinensis that also contains a cyclic backbone. We show that MCoTI-II is a significantly more potent matriptase inhibitor than SFTI-1 and that all alanine mutants of both peptides, generated using positional scanning mutagenesis, have decreased trypsin affinity, whereas several mutations either maintain or result in enhanced matriptase inhibitory activity. These intriguing results were used to design one of the most potent matriptase inhibitors known to date with a 290 pm equilibrium dissociation constant, and provide the first indication on how to modulate affinity for matriptase over trypsin in cyclic peptides. This information might be useful for the design of more selective and therapeutically relevant inhibitors of matriptase.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos Cíclicos / Proteínas de Plantas / Serina Endopeptidases / Inibidores de Serina Proteinase Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos Cíclicos / Proteínas de Plantas / Serina Endopeptidases / Inibidores de Serina Proteinase Idioma: En Ano de publicação: 2013 Tipo de documento: Article